Neurocrine Biosciences Financial Statements
NASDAQ: NBIXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Neurocrine Biosciences revenue and earnings
In fiscal 2025, Neurocrine Biosciences generated $2.86 billion in revenue, up 21.4% from fiscal 2024, its 9th consecutive year of revenue growth. Net income was $478.6 million (+40.2% year over year), for a net margin of 16.7% versus a median of 13.2% in the prior 5 years. Gross margin was 98.2% (down from 98.6%) and operating margin 21.6%.
Diluted earnings per share came in at $4.67, up from $3.29. Over the last 5 fiscal years, NBIX's revenue has grown at a 22.3% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Neurocrine Biosciences income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.86B | 2.36B | 1.89B | 1.49B | 1.13B | 1.05B | 788.10M | 451.20M | 161.63M | 15.00M |
| Revenue growth (YoY) | +21.45% | +24.81% | +26.76% | +31.34% | +8.38% | +32.71% | +74.67% | +179.16% | +977.51% | -24.12% |
| Cost of Revenue | 52.10M | 34.00M | 39.70M | 23.20M | 14.30M | 10.10M | — | 4.89M | 1.25M | 0 |
| Gross Profit | 2.81B | 2.32B | 1.85B | 1.47B | 1.12B | 1.04B | — | 446.31M | 160.37M | 15.00M |
| Operating Expenses | 2.19B | 1.75B | 1.60B | 1.22B | 1.03B | 882.90M | 715.80M | 414.40M | 292.99M | 162.37M |
| Research & Development | 1.02B | 731.10M | 565.00M | 463.80M | 328.10M | 275.00M | — | 160.52M | 121.83M | 94.29M |
| Selling, General & Admin | 1.16B | 1.01B | 887.60M | 752.70M | 583.30M | 433.30M | 354.10M | 248.90M | 169.91M | 68.08M |
| Operating Income | 619.10M | 570.50M | 250.90M | 249.00M | 102.50M | 163.00M | 72.30M | 36.80M | -131.36M | -147.37M |
| Interest Expense | — | — | 4.60M | 7.10M | 25.80M | 32.80M | 32.00M | 30.50M | 19.52M | 0 |
| Other Income (Expense) | 86.30M | -84.50M | 81.20M | -35.10M | -1.10M | -56.30M | -25.80M | -15.00M | -11.18M | 6.28M |
| Pretax Income | 705.40M | 486.00M | 332.10M | 213.90M | 101.40M | 106.70M | 46.50M | 21.80M | -142.54M | -141.09M |
| Income Tax | 226.80M | 144.70M | 82.40M | 59.40M | 11.80M | -300.60M | 9.50M | 700.00K | 0 | 0 |
| Net Income | 478.60M | 341.30M | 249.70M | 154.50M | 89.60M | 407.30M | 37.00M | 21.10M | -142.54M | -141.09M |
| Net Income growth (YoY) | +40.23% | +36.68% | +61.62% | +72.43% | -78.00% | +1000.81% | +75.36% | — | — | — |
| EPS (Basic) | 4.81 | 3.40 | 2.56 | 1.61 | 0.95 | 4.38 | 0.40 | 0.23 | -1.62 | -1.63 |
| EPS (Diluted) | 4.67 | 3.29 | 2.47 | 1.56 | 0.92 | 4.16 | 0.39 | 0.22 | -1.62 | -1.63 |
| Shares Outstanding (Basic) | 99.50M | 100.40M | 97.70M | 95.80M | 94.60M | 93.10M | 91.60M | 90.20M | 88.09M | 86.71M |
| Shares Outstanding (Diluted) | 102.50M | 103.70M | 101.00M | 98.90M | 97.90M | 97.80M | 95.70M | 95.40M | 88.09M | 86.71M |
| EBITDA | 645.10M | 594.00M | 268.70M | 264.10M | 113.40M | 171.60M | 79.70M | 40.82M | -128.96M | -145.92M |
| Gross Margin | 98.18% | 98.56% | 97.90% | 98.44% | 98.74% | 99.03% | — | 98.92% | 99.22% | 100.00% |
| Operating Margin | 21.64% | 24.22% | 13.30% | 16.73% | 9.04% | 15.58% | 9.17% | 8.16% | -81.27% | -982.48% |
| Net Margin | 16.73% | 14.49% | 13.23% | 10.38% | 7.90% | 38.94% | 4.69% | 4.68% | -88.19% | -940.60% |
This table shows 10 annual periods of Neurocrine Biosciences's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow NBIX's reporting calendar. What is a income statement?